Fig 1: Validation of the optimized matrix by stabilization of biomarkers representing various storage sensitivities.Optimized matrix (EX, red bars) post-rehydration recovery comparison with the fresh, untreated control; highlighted by the connecting bar. (A) CRP: Complete stabilization (99±3%; P = 0.58) (B) PSA: Complete stabilization (99±4%; P = 0.47) (C) MMP-7: Significantly lower recovery post-rehydration (94±3%; P = 0.0015) (D) C3a: Significantly higher level post-rehydration (106±1%; P = 0.003). Error bars represent standard deviation from at least three independent experiments. Statistically significant difference is denoted by *s (p ≤ 0.05), while non-significant difference is denoted by ns.
Fig 2: The probability densities of log PSA data of NZ-European, US-AA and US-EA controls. All violin plots are provided with the median and inter-quartile ranges. NZ-European controls = NZ controls cohort with self-reported European ethnicity. US-AA = African American controls cohort. US-EA = European American controls cohort.
Fig 3: Correlation scatter plots between age and log PSA at recruitment for NZ-European controls and age and log PSA at diagnosis for NZ-non-MPEA, US-AA, US-EA, TW1 and TW2 cases stratified by the AKR1C3 rs12529 genotypes. All plots are presented with linear trend lines. NZ-European controls = NZ controls cohort with self-reported European ethnicity. NZ-non-MPEA cases = New Zealand cases self-identified as European or from the Indian sub-continent, Middle-East and others. US-AA = African Americans cases cohort. US-EA = European Americans cases cohort. TW1 = Taiwanese cases cohort with advanced prostate cancer who were on androgen-deprivation therapy. TW2 = Taiwanese cases cohort with localized prostate cancer who underwent RP as initial treatment.
Fig 4: Association of socio-demographic and clinical characteristics with systemic immune-oncological proteins in Ghanaian (n = 654), AA (n = 374), and EA (n = 454) men without prostate cancer.The association of the 82 immuno-oncological proteins (as continuous variables) with age, BMI, education, aspirin use, smoking, diabetes, and PSA was assessed in men without prostate cancer using a multivariable linear regression test. P values were adjusted for multiple comparison. An analyte was considered significantly associated with clinical and socio-demographic covariables if the multivariable model yielded a false discovery rate (FDR)-adjusted P < 0.05 on the F-statistic. Analytes that did not have a significant association with any of the clinical/sociodemographic variables in at least one of the population groups are not presented in the heatmap. Blue represents a negative association while red represents a positive association. The significance level (FDR-adjusted two-sided P value-based) for each association is color-coded. Source data are provided as a Source Data file. TI tumor immunity, AA African American, and EA European American.
Fig 5: The probability densities of log PSA data of NZ-all, US-AA, US-EA, TW1 and TW2 cases. All violin plots are provided with the median and inter-quartile ranges. NZ-all = All NZ cases consisting of 94.2% European, 3.3%-Maori, Pacific and East Asian (MPEA); 2.5% from the Indian sub-continent and Middle-Eastern and others. US-AA = African American cases cohort. US-EA = European American cases cohort. TW1 = Taiwanese cohort with advanced prostate cancer who were on androgen-deprivation therapy. TW2 = Taiwanese cohort with localized prostate cancer who underwent RP as initial treatment.
Supplier Page from Abcam for Human Total Prostate Specific Antigen ELISA Kit